Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockRule-based from financial data. Not advice.
Historically, Apr has averaged the highest return (+13.7%); Mar the lowest (-8.5%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.6%Negative MonthJan 2026: -7.62% | -3.5%Negative MonthFeb 2026: -3.54% | -13.0%Negative MonthMar 2026: -12.97% | +17.4%Positive MonthApr 2026: +17.42% | +1.7%Neutral MonthMay 2026: +1.71% | -0.9%Neutral MonthJun 2026: -0.93% | +7.8%*Positive MonthJul 2026: +7.77% | β | β | β | β | β |
| 2025 | -11.9%Negative MonthJan 2025: -11.91% | -13.4%Negative MonthFeb 2025: -13.42% | -3.3%Negative MonthMar 2025: -3.29% | +2.6%Positive MonthApr 2025: +2.63% | +27.6%Positive MonthMay 2025: +27.58% | +3.0%Positive MonthJun 2025: +3.02% | +10.5%Positive MonthJul 2025: +10.50% | -7.3%Negative MonthAug 2025: -7.31% | +3.5%Positive MonthSep 2025: +3.49% | +1.0%Neutral MonthOct 2025: +0.98% | -13.3%Negative MonthNov 2025: -13.30% | -3.2%Negative MonthDec 2025: -3.19% |
| 2024 | +7.6%Positive MonthJan 2024: +7.61% | -5.5%Negative MonthFeb 2024: -5.49% | -12.8%Negative MonthMar 2024: -12.77% | +16.3%Positive MonthApr 2024: +16.30% | -5.8%Negative MonthMay 2024: -5.83% | +6.1%Positive MonthJun 2024: +6.10% | +1.4%Neutral MonthJul 2024: +1.37% | +14.1%Positive MonthAug 2024: +14.10% | -12.0%Negative MonthSep 2024: -12.01% | -5.7%Negative MonthOct 2024: -5.74% | -4.6%Negative MonthNov 2024: -4.57% | -0.2%Neutral MonthDec 2024: -0.18% |
| 2023 | -12.8%Negative MonthJan 2023: -12.85% | -8.6%Negative MonthFeb 2023: -8.61% | -7.8%Negative MonthMar 2023: -7.81% | +24.6%Positive MonthApr 2023: +24.60% | +3.8%Positive MonthMay 2023: +3.79% | +6.4%Positive MonthJun 2023: +6.35% | +28.0%Positive MonthJul 2023: +28.05% | -3.8%Negative MonthAug 2023: -3.81% | -4.9%Negative MonthSep 2023: -4.92% | -13.7%Negative MonthOct 2023: -13.69% | +3.5%Positive MonthNov 2023: +3.48% | +0.6%Neutral MonthDec 2023: +0.64% |
| 2022 | -7.5%Negative MonthJan 2022: -7.46% | -9.5%Negative MonthFeb 2022: -9.53% | -5.8%Negative MonthMar 2022: -5.84% | +7.5%Positive MonthApr 2022: +7.48% | -7.6%Negative MonthMay 2022: -7.60% | -5.1%Negative MonthJun 2022: -5.14% | +3.4%Positive MonthJul 2022: +3.38% | +3.3%Positive MonthAug 2022: +3.31% | +8.4%Positive MonthSep 2022: +8.43% | +2.4%Positive MonthOct 2022: +2.42% | -5.7%Negative MonthNov 2022: -5.67% | +1.7%Neutral MonthDec 2022: +1.72% |
| 2021 | β | β | β | β | β | -2.3%Negative MonthJun 2021: -2.31% | -5.6%Negative MonthJul 2021: -5.64% | -7.8%Negative MonthAug 2021: -7.78% | -1.3%Neutral MonthSep 2021: -1.32% | -3.6%Negative MonthOct 2021: -3.61% | -13.6%Negative MonthNov 2021: -13.56% | +7.5%Positive MonthDec 2021: +7.51% |
| AvgΒ±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position β all Januaries together, all Februaries together, and so on β to show whether a given month has leaned positive or negative historically. βSimpleβ counts each month as +1 or β1. βWeightedβ gives larger moves more influence: +2 above +10%, β2 below β10%. With only 6 years of history for this asset, each monthβs score reflects a small number of observations β read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the assetβs full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each dayβs closing price by the price on January 1st of that year (or the assetβs first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in βAverage fromβ, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ2.17 K Cr | β | βΉ157.00 Cr | β | β | 12.5% | -4.1% | 10.6% |
| Mar 2024 | βΉ2.27 K Cr | β | βΉ142.00 Cr | β | β | 12.1% | -9.2% | -7.2% |
| Mar 2023 | βΉ2.50 K Cr | β | βΉ153.00 Cr | β | β | 13.7% | 11.0% | -21.5% |
| Mar 2022 | βΉ2.25 K Cr | β | βΉ195.00 Cr | β | β | 20.0% | 17.5% | -24.4% |
| Mar 2021 | βΉ1.92 K Cr | β | βΉ258.00 Cr | β | β | 30.0% | 17.1% | 89.7% |
| Mar 2020 | βΉ1.64 K Cr | β | βΉ136.00 Cr | β | β | 21.9% | 12.4% | 56.3% |
| Mar 2019 | βΉ1.45 K Cr | β | βΉ87.00 Cr | β | β | 16.8% | 27.5% | 19.2% |
| Mar 2018 | βΉ1.14 K Cr | β | βΉ73.00 Cr | β | β | 16.8% | 4.7% | -2.7% |
| Mar 2017 | βΉ1.09 K Cr | β | βΉ75.00 Cr | β | β | 19.4% | 1.2% | 13.6% |
| Mar 2016 | βΉ1.08 K Cr | β | βΉ66.00 Cr | β | β | 18.9% | -1.0% | -15.4% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Net Sales | 972 | 1,087 | 1,076 | 1,089 | 1,140 | 1,454 | 1,635 | 1,915 | 2,251 | 2,498 | 2,267 | 2,174 | 2,237 |
| Total Expenses | 822 | 915 | 900 | 910 | 955 | 1,252 | 1,387 | 1,511 | 1,930 | 2,212 | 1,998 | 1,908 | 1,949 |
| EBIT / Operating Profit | 150 | 172 | 176 | 179 | 185 | 203 | 248 | 404 | 321 | 286 | 269 | 265 | 288 |
| OPM % | 15% | 16% | 16% | 16% | 16% | 14% | 15% | 21% | 14% | 11% | 12% | 12% | 13% |
| Other Income | 1 | 1 | 0 | 4 | 1 | 6 | 9 | 7 | 5 | 2 | 4 | 14 | 14 |
| Finance Costs | 37 | 42 | 47 | 38 | 36 | 41 | 36 | 26 | 23 | 36 | 33 | 32 | 28 |
| Depreciation & Amortisation | 28 | 31 | 36 | 37 | 38 | 40 | 47 | 48 | 47 | 47 | 48 | 48 | 50 |
| Profit Before Tax | 86 | 100 | 93 | 108 | 112 | 128 | 175 | 338 | 256 | 205 | 192 | 199 | 224 |
| Tax % | 28% | 22% | 29% | 30% | 35% | 32% | 22% | 24% | 24% | 25% | 26% | 21% | - |
| Net Profit / PAT | 62 | 78 | 66 | 75 | 73 | 87 | 136 | 258 | 195 | 153 | 142 | 157 | 190 |
| EPS (βΉ) | 6.38 | 8.01 | 6.84 | 7.91 | 7.78 | 9.25 | 14.56 | 27.65 | 21.06 | 16.50 | 15.43 | 17.24 | 20.87 |
| Dividend Payout % | 26% | 41% | 25% | 3% | 3% | 3% | 3% | 9% | 5% | 6% | 6% | 6% | - |
Peer Comparison
Materials sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Aarti Drugs Limitedthis co. | βΉ3.60 K Cr | βΉ2.17 K Cr | 18.90 | 2.68 | 14.06 | -4.1% |
| UltraTech Cement Ltd | βΉ3.55 L Cr | βΉ71.89 K Cr | 48.60 | 5.02 | 27.23 | 4.7% |
| JSW Steel Limited | βΉ2.88 L Cr | βΉ1.28 L Cr | 38.00 | 3.45 | 14.23 | -5.5% |
| Asian Paints Ltd. | βΉ2.77 L Cr | βΉ29.55 K Cr | 69.60 | 14.50 | 35.04 | -5.4% |
| Hindustan Zinc Ltd. | βΉ2.66 L Cr | βΉ33.97 K Cr | 25.50 | 19.57 | 18.58 | 17.4% |
| Coal India Limited | βΉ2.64 L Cr | βΉ1.59 K Cr | 12.40 | 13.24 | 16.33 | 5.1% |
| Vedanta Limited | βΉ2.49 L Cr | βΉ74.30 K Cr | 26.50 | 3.37 | 12.82 | 5.0% |
| Industry Average | β | βΉ10.75 K Cr | 47.54 | 5.23 | 30.19 | 121.8% |
